key: cord-0255470-8s8grn8f
authors: Murali, S.; Sakthivel, M.; P, K.; Venkataswamy, V.; Thangaraj, J. W. V.; Shete, A.; John, A.; Arjun, J.; C P, G. K.; Yadav, P. D.; Sahay, R.; Majumdar, T.; Dhudhmal, M.; Sivalingam, A.; D, S. R.; D, A.; R, V.; M, M. M.; A, S.; M, P.; G, E.; C, P.; S, D. P. V.; P, E.; Parasuraman, G.; M, J.; Narnaware, M. S.; Bedi, G. S.; Kaur, P.; Murekhar, M. V.
title: Effectiveness of ChAdOx1 nCoV-19 Corona Virus Vaccine (CovishieldTM) in preventing SARS-CoV2 infection, Chennai, Tamil Nadu, India, 2021
date: 2022-04-16
journal: nan
DOI: 10.1101/2022.04.15.22273859
sha: 8ad383408aac44a95b3f1a2cfb464f9d2baa5de7
doc_id: 255470
cord_uid: 8s8grn8f

Background: India experienced the second wave of the COVID-19 pandemic in March 2021, driven by the delta variant. Apprehensions around the usefulness of vaccines against delta variant posed a risk to the vaccination program. Therefore, we estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against COVID-19 infection among individuals [≥]45 years in Chennai, India. Methods: A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai, Tamil Nadu. The estimated sample size was 10,232. We enumerated individuals from all eligible households and periodically updated vaccination and COVID-19 infection data. We computed vaccine effectiveness with its 95% confidence interval for two doses of the Covishield vaccine against any COVID-19 infection. Results: We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. The overall incidence of COVID-19 infection was 1099 per 100,000 population. The vaccine effectiveness against COVID-19 disease in the [≥]45 age group was 61.3% (95% CI: 43.6 - 73.4) at least two weeks after receiving the second dose of Covishield. Genomic analysis of 74 (28 with two doses, 15 with one dose, and 31 with zero dose) out of the 90 aliquots collected from the 303 COVID-19 positive individuals in the 45+ age group showed delta variants and their sub-lineages. Conclusion: We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.

World Health Organization (WHO) declared COVID-19 disease as a pandemic in March 2020 (1) . India reported its first COVID-19 case on January 30, 2020 (2) . The first wave of the disease in India peaked in mid-September and declined gradually by October 2020. The country witnessed the second wave from February to July 2021, with new cases reaching over 400,000 per day (3). COVID-19 deaths were reportedly higher among older adults and individuals with chronic morbid conditions (2) . Chennai, the capital city of Tamil Nadu state . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 Nadu, India, between December to May 2021 were due to delta variant (8) . Pooled analysis from three randomized controlled trials conducted in the United Kingdom, Brazil, and South Africa documented the efficacy of ChAdOx1 nCoV-19 (AZD1222) at around 70% (7). Few studies demonstrated the immune evasion property of the delta variant (B.1.617.2) and reduced effectiveness of vaccines (9) (10) (11) . Although there is ample evidence for the effectiveness of the COVID-19 vaccine in preventing severe diseases (12) (13) (14) , there was limited data regarding its effectiveness in preventing the infection.

In this context, a collaborative team from GCC and a public health research institution conducted a community-based study documenting vaccine effectiveness (VE). Our primary objective was to estimate the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against RT-PCR confirmed COVID-19 infection among the individuals ≥45 years during the second wave of COVID-19 driven by the delta variant, Chennai, India.

We also determined the distribution of SARS-CoV-2 Variants of concern (VoC) among a sample of individuals diagnosed with COVID-19.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022 

We conducted a community-based cohort study in Chennai from May 22, 2021, to September 30, 2021. Chennai is India's 4th largest metropolitan city and the capital city of Tamil Nadu State, India. Greater Chennai Corporation (GCC) is divided into north, south, and central regions, with five zones each. Each zone is further divided into divisions, and there are 200 divisions. We established the cohort in three divisions and collected data using the COVID-19 surveillance system established by GCC (15) .

Chennai registered its first COVID-19 cases on March 14, 2020. The city reported f 5,66,147 individuals positive for COVID-19 from the pandemic's start till December 31, 2021. As a part of COVID-19 mitigation strategies, GCC has been conducting active surveillance, contact tracing, mobile testing, and positive patient follow-up. For active door-to-door, syndromic surveillance, GCC recruited temporary paid volunteers named Fever Survey Workers (FSWs) who visited every household at least twice a week to enquire about symptoms suggestive of COVID-19. They motivated individuals with at least one of these symptoms to get tested for COVID-19 free of cost at the nearest testing facility. In addition, symptomatic patients also sought care at the government or private health facilities. All health facilities across the city sent their samples for the RT-PCR tests for COVID-19 disease to the government-authorized laboratory. All laboratories uploaded the COVID-19 RT-PCR test results into a specially designed web portal named "igotit," which generated line lists for every division. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022 medical team provided essential medication and counseling for patients in home isolation.

The medical team referred the patients requiring hospitalization to designated COVID-19 hospitals based on the triaging. The telemedicine team at the zonal level monitored the patients for any red flags daily and directed them to the hospital if needed.

We conducted the study during the declining phase of the second wave of COVID-19 in Inclusion Criteria: We included all individuals who gave consent in the study area. India opened the COVID-19 vaccination camp for the 18-45 age group from May 1, 2021. Hence the coverage for this age group was low and limited to one dose only. Similarly, the coverage for Covaxin was only 12% in the study population. Therefore, we included only the 45+ age group for estimating the vaccine effectiveness of Covishield.

Exclusion Criteria: We excluded non-household settlements such as hostels, paying guests facilities, and residential hotels. All individuals who tested positive for COVID-19 during the study period from June 2021 to September 2021 were followed up to assess their disease outcomes.

Given the high transmission of variants of concern, we assumed 70% VE for the sample size calculation (7, 16, 17) . Based on the surveillance data for the two peak months in the first wave, we considered the attack rate among the unvaccinated group as 2%, the confidence . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We formed field teams consisting of supervisors with research experience and GCC Fever Survey Workers. The FSWs visited each household in the area assigned to them to assess their eligibility. After obtaining written informed consent from the eligible households, we assigned a unique identification number. We collected baseline data, including sociodemographic details, residential area details (slum/non-slum), and housing patterns (number of living rooms & total individuals in the house). We collected comorbidity status, history of previous COVID-19 infection, current COVID-19 disease, and vaccination details using an Open Data Kit Tool (ODK) (19) . We updated the exposure and outcome data periodically until September 30, 2021.

We confirmed the vaccination status by verifying the vaccination card given to the patient (based either on the message received in the beneficiary phone number or the vaccination certificate downloaded from the portal exclusively maintained by MoHFW for COVID-19 vaccination (COWIN). We defined unvaccinated individuals as those who have not received the COVID-19 vaccine or were within 14 days of receiving the first dose.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 We defined vaccination with single-dose as individuals who had completed 14 days after receiving the first dose of vaccine and had not received the second dose. The individuals who received the second dose but were within 14 days were also considered in this category.

Vaccination with two doses included individuals who had completed 14 days after receiving the second dose of the vaccine.

The primary outcome measure was RT-PCR confirmed COVID-19 infection. We collected the line list of positive individuals. Fourteen days after the confirmation of diagnosis, the data collectors telephonically interviewed the individuals. We ascertained the clinical outcome of the COVID-19 infection as recovered or dead. Among recovered, we collected hospitalization details and documented the self-reported need for ventilator or oxygen support. If a COVID-19 positive individual died within 28 days from the date of diagnosis of the COVID-19 disease, we considered the event as COVID death. However, death due to non-natural causes (e.g., accidental, intentional self-harm, and homicide) was not deemed as COVID-19 death even if it was within 28 days from the date of diagnosis for COVID-19 disease (20) .

We collected nasal and oro-pharyngeal (N/OP) swabs from RT-PCR confirmed COVID-19 patients aged above 45 years. The team shipped an aliquot of the COVID-19 positive samples to ICMR-National Institute of Virology, Pune for Next-Generation Sequencing (NGS).

Viral RNA was extracted (N/OP) from swab samples using an RNA extraction kit (Applied Biosystem, Waltham, MA, USA) and tested for the detection of the E gene using Real-time RT-PCR) (21) . We included samples having Ct <30 for NGS. In brief, the COVIDSeq . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

For the primary analysis of the vaccine for Covishield, we excluded all individuals who were less than 45 years or took vaccines other than Covishield. We also excluded the individuals who had taken the first dose of the vaccine within 14 days or reported past infection with COVID-19.

We calculated the mean (standard deviation) and median (Inter-quartile range) for age. After which, we calculated frequencies and proportions for socio-demographics for overall respondents and 45-98 years of age group. We summarized the vaccine-related and outcome- 

We obtained approval from the Institutional Ethics committee and obtained required administrative approvals. We conducted extensive training sessions for the Fever Survey Workers to collect data while ensuring privacy and comfort of respondents. We obtained written informed consent from the participants before enrolling them in the cohort.

FSWs referred individuals requiring emotional support during the follow-up visits. We conducted the interviews adhering to the COVID-19 personal protection guidelines and maintained complete confidentiality and anonymity of the data. Trained Laboratory technicians collected the throat and nasal swabs wearing full PPE Kit and followed all aseptic precautions.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 

Of the 20,913 households in the three divisions in Chennai, India, 19,211 (92%) were enrolled in the cohort (Figure 1) . A total of 69,435 individuals were residing in the enrolled households. One-fifth (n=3,466; 18%) of the households were in slum areas, and 95.5% were pucca houses (Supplementary Table 1 We included 21,793 individuals ≥45 years for the analysis of vaccine effectiveness (Table 1) .

About 60% (n=13,114) belonged to the 45-59 age group, and nearly half (n=10,916; 50.1%) were males. The proportion of health care and frontline workers was 2.4% (n=532).

Of the 21,793 individuals in the 45+ age cohort, 7,735 (36%) were unvaccinated. About half (n=10,762; 49.4%) of the 45+ cohort population received Covishield vaccine ( Table 2 ). The vaccination coverage was almost similar among males (n=7,191; 66%) and females (n=6,867; 63%). The coverage with at least one dose was highest (n=5,703; 65.7%) among the elderly (≥60 years), followed by the 45-59 age group (n=8,355; 63.7%).

In the 45+ cohort of 21,793 individuals, 303 tested positive for COVID-19, with an incidence of 1,390 per 100,000 population during the study period (Supplementary Table 5 ). Among . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (Table 3 ). The incidence was higher among females (1,260 per 100,000) than males (1,032 per 100,000). The incidence was almost similar in the 45-59 age group (1,141 per 100,000) and the 60+ age group (1,145 per 100,000) .

Among the 123 individuals who had COVID-19, 5.7% (n=7) recovered with oxygen, and 87.8% (n=108) recovered without oxygen. The proportion of COVID-19 patients who required oxygen was 8.2% (n=4) in the 60+ age group and 4.1% (n=3) in the 45-59 age group (Table 3) . Of the 2 (1.6%) COVID-19 deaths, both were ≥60 years of age.

We excluded 3,296 individuals vaccinated with Covaxin and vaccines other than Covishield for the primary analysis of vaccine effectiveness (VE). Among the 7,735 unvaccinated individuals, we excluded 81 (1%) individuals who had past infections of COVID-19.

Similarly, we excluded 59 (<1%) individuals from among the 6,710 individuals vaccinated with two doses of Covishield Vaccine from the analysis for VE analysis (Figure 1 ). We also calculated the RR and VE for the various subgroups within the 45+ cohort. After adjusting for the number of individuals per room in the household, the VE estimates showed . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 

We could collect aliquots for 90 samples out of the 303 COVID-19 patients in the >=45 years of age from the respective testing laboratory. Out of 90 samples received at ICMR NIV Pune, only 75 (83%) samples had a CT value less than 30. We processed these 30 samples for NGS.

E gene copy numbers were found to be similar in the unvaccinated (7.7 x 10 1 to 2.1 x 108), one dose (5.2 x 10 1 to 6.0 x 108) and two-dose (7.1 x 10 1 to 3.4 x 109) vaccinated groups.

We could retrieve genome > 98% from 67 samples. Therefore, we performed GSAID on the Covishield vaccine. Two mutations of concern and interest in the RBD with evidence of increasing transmissibility or virulence, L452R, and T478K, were detected in 57 and 59 out of 67 samples, respectively. One of the mutations of concern in the furin cleavage site, P681R, was found in all the sequences retrieved in the current study. All the above mutations were seen as a result of transversion of single nucleotide variants (SNV) (Supplementary Figure 4) .

We conducted this study towards the latter half of the second wave, which overwhelmed the health system due to increased hospitalization. The study was initiated to generate locally relevant evidence to build trust in the effectiveness of the COVID-19 vaccine. Our study documented vaccine effectiveness (VE) in a community cohort during the surge due to delta variant in a metropolitan city in India. Two doses of Covishield effectively protected the population above 45 years from COVID-19 infection. The study included all sections of a population, hence generating data closer to the real-world setting. It was challenging to develop a community cohort in a pandemic setting due to the high burden on the health care workers on the field, apprehensions among the population, and poor linkages between disease and vaccination data. The available resources of GCC, trust among the public towards FSWs, and complementary expertise of the collaborators enabled the planning and execution of this study.

Our study reiterates the protective effect of vaccines against RT-PCR confirmed COVID-19 infection as reported in three other studies from India. Our study's VE estimates against COVID-19 disease were lower than those among a cohort of healthcare workers and comparable to two other studies from India (12) (13) (14) . The first study had unique characteristics, such as a large nationwide cohort that included relatively younger healthy . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 16 16 HCWs and FLWs. The cohort size was 1.6 million with 82% two-dose coverage of any COVID-19 vaccine and reported VE of 94.9% during January -May 2021 (12) . The second study conducted during April -May 2021 using a test-negative case-control design among 4360 individuals (2379 cases and 1981 controls) estimated 63% VE for two doses of Covishield in Delhi, India (14) . The third study was among a cohort of 10,567 health care workers, predominantly vaccinated with Covishield, and reported a VE of 65% from Feb to May 2021 in Tamil Nadu, India (13) . Irrespective of the study design or study population, the results consistently supported the usefulness of two doses of Covishield.

The VE in our study was also comparable to the studies from other countries for India's vaccination program had two approved vaccines produced in India during the study period. The availability of manufacturing facilities in the country enabled rapid scaling of the vaccination program. A metanalysis pooled available data for multiple vaccines against delta . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 vaccine, availability at scale and operationalization of vaccination program offered reasonable protection to the population against delt variant infection.

One of the limitations of the present study was the failure to ascertain the previous infection in the cohort using serology. However, the proportion of asymptomatic infection might have been similar in both vaccinated and non-vaccinated groups. The second limitation was an underestimation of symptomatic infections. We tried to overcome this limitation by using active surveillance for symptomatic infections and testing all symptomatic individuals and contacts. We pooled the line list of all COVID-19 positive individuals tested in any of the labs in the city to ensure the completeness and representativeness. However, we might have missed individuals who did not reveal their symptom status and did not get tested.

The third limitation was the inadequate sample size to study the VE against severe infections.

Our primary objective was to understand the protective effect of COVID-19 vaccines irrespective of the severity of disease in the general population. As the cases started declining after May 2021, the number of hospitalization were inadequate for subgroup analysis.

However, there is adequate evidence to support the usefulness of COVID-19 vaccines in preventing severe infection in India. Two hospital-based case-control studies among RT-PCR tested individuals reported around 80% effectiveness of Covishield (14, 27) . The effectiveness was 92-94% among a cohort of HCWs predominantly vaccinated with Covishield (13).

Two doses of the Covishield (ChAdOx1 nCoV-19) vaccine protected the adult population from the delta variant of COVID-19 infection in Chennai, India. We may require similar VE studies at the population level in the context of changing variants and newer vaccines and . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.15.22273859 doi: medRxiv preprint 18 18 boosters. The disease surveillance and vaccination program databases are currently separate, limiting the opportunities for systematic periodic analysis of outcomes. We recommend linkages between the disease surveillance and vaccination databases at the district or state level to enable regular in-depth real-time analysis. High vaccination coverage of two doses should be ensured to maintain population-level immunity against COVID-19 infection.

SM and MS contributed equally to the paper as joint first authors. MM, PK, PG, MS, and SM designed the study, planned data analysis, and wrote the first draft of the paper. KP and VV managed and analyzed the data and reviewed the manuscript. JT, GK, and SR helped in designing, and data acquisition, and gave critical comments on the genome sequencing component of the study. AS, PY, RS, TM, and MD did data acquisition, and prepared the first draft of the genome sequencing component of the study. AS, AD, VR, MM, SA, PM, PM, DS, PC, EP, and EG did data acquisition, and analysis. JA, JM, MN, and GB coordinated the data acquisition, interpreted the data, and helped revise the manuscript. JT, and MM gave critical comments and revised the manuscript. All authors approved the final manuscript. PK is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. The views presented here are those of the authors and should not be attributed to ICMR-NIE.

We thank all the Greater Chennai Corporation health staff, including Zonal Health Officers, doctors, nurses, field staff, volunteers who coordinated with the research team in door-todoor data collection. We extend our sincere gratitude to the printing press department of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 16, 2022. ; https://doi.org/10.1101/2022.04.15.22273859 doi: medRxiv preprint Greater Chennai Corporation for providing the required prints in a timely manner. We acknowledge the contribution of Aswini S, Amirthammal Guna Grace, Vignesh, G Keerthiga, and Swapna R who provided the required technical support to the data team of the study. We thank the technical staff R Sudha, P. Lourdu Stella Mary, M.R. Santhi, I. Kalaimani, T.

Ravichandran, T. Subba Rao, K. Ramu, P. Shantha, and Gandhimathi who helped in physical scrutiny of the data entry forms being filled from the field. We also thank the "igotit" data team who provided the required support in their portal to accommodate the vaccine coverage data. Authors are grateful for the excellent support provided by Dr. Abinendra Kumar, Mrs.

Savita Patil, Mr. Yash Joshi, Ms Pranita Gawande, Ms. Jyoti Yemul for processing of the samples for NGS.

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

WHO Director-General's opening remarks at the media briefing on COVID-19

Lessons learnt during the first 100 days of COVID-19 pandemic in India

COVID-19 Vaccine FAQs

Serum Institute Of India -ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) -COVISHIELD

COVAXIN -India's First Indigenous Covid-19 Vaccine | Bharat Biotech

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials -The Lancet

Delta variant may have caused widespread COVID-19 infection in TN: Study

The News Minute

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of INdian Armed Forces: Interim results of VIN-WIN cohort study

Protective Effect of COVID-19 Vaccine Among Health Care Workers During the Second Wave of the Pandemic in India

Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted

Epidemiology of COVID-19 and effect of public health interventions

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial -The Lancet

Sample size calculator for evaluation of COVID-19 vaccine effectiveness (Excel)

ODK -Collect data anywhere

COVID Death Definition

Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India

The authors have declared no conflicts of interest.. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 20 20 It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 16, 2022